论文部分内容阅读
中比合资——西安杨森制药有限公司是我国医药行业目前规模最大、品种最多、剂型最全的先进技术型企业。总投资为1.52亿元人民币,其中外方出资52%,中方出资48%。1989年初竣工,同年4月份开始试生产。经过合资双方一年多的努力,生产经营机制已经全面运转,并出现了令人鼓舞的成绩。自投产至今年4月底,累计销售额达3.5亿元,获纯利6,600万元。这等于一年半时间就可收回一个西安杨森。为什么能在不到两年时间内就取得如此高的经济效益?其成功之因素在于以下几个方面: (一) 本着“忠实于科学,献身于健康”的宗旨,树立良好的公司形象
Sino-Belgian Joint Venture-Xi’an Janssen Pharmaceutical Co., Ltd. is an advanced technology enterprise with the largest scale, the most variety, and the most complete dosage form in China’s pharmaceutical industry. The total investment is RMB 152 million, of which 52% is invested by foreign parties and the Chinese side contributes 48%. Completed in early 1989 and began trial production in April of the same year. After more than a year of efforts by the joint venture partners, the production and operation mechanism has been fully operational and encouraging results have emerged. From the start of production until the end of April this year, the cumulative sales amounted to 350 million yuan and net profit of 66 million yuan. This equals one and a half years to recover a Xian Janssen. Why can we achieve such high economic benefits in less than two years? The factors for its success lie in the following aspects: (1) Establishing a good corporate image based on the tenet of “faithfulness to science and dedication to health”